UBS Group’s Axcella Health Inc. Common Stock AXLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-106
Closed -$1.11K 10562
2023
Q3
$1.11K Buy
106
+70
+194% +$551 ﹤0.01% 8100
2023
Q2
$196 Sell
36
-213
-86% -$2K ﹤0.01% 8404
2023
Q1
$2.98K Buy
+249
New +$3.32K ﹤0.01% 8406
2022
Q4
Sell
-125
Closed -$5K 11440
2022
Q3
$5K Sell
125
-97
-44% -$5.16K ﹤0.01% 9272
2022
Q2
$11K Buy
222
+97
+78% +$4.77K ﹤0.01% 7897
2022
Q1
$8K Buy
125
+51
+69% +$2.55K ﹤0.01% 8747
2021
Q4
$4K Sell
74
-152
-67% -$10.7K ﹤0.01% 9583
2021
Q3
$16K Sell
226
-45
-17% -$3.85K ﹤0.01% 7450
2021
Q2
$27K Sell
271
-38
-12% -$3.77K ﹤0.01% 7054
2021
Q1
$37K Buy
309
+191
+162% +$26.9K ﹤0.01% 6838
2020
Q4
$15K Buy
118
+63
+115% +$8.09K ﹤0.01% 7185
2020
Q3
$6K Sell
55
-70
-56% -$8.63K ﹤0.01% 7253
2020
Q2
$17K Sell
125
-237
-65% -$29K ﹤0.01% 6667
2020
Q1
$31K Sell
362
-401
-53% -$41.1K ﹤0.01% 6193
2019
Q4
$76K Buy
763
+703
+1,172% +$77.3K ﹤0.01% 6134
2019
Q3
$9K Sell
60
-6
-9% -$1.11K ﹤0.01% 7235
2019
Q2
$15K Buy
+66
New +$20.9K ﹤0.01% 6823

Other funds holding AXLA

UBS Group's AXLA Position: Q4 2023 in Review

UBS Group sold out of Axcella Health Inc. Common Stock (AXLA) in Q4 2023, closing a stake of 106 shares — an estimated $1.11K sold.

UBS Group first reported a position in AXLA in Q2 2019 and held it in 17 quarters. The position peaked at $76K in Q4 2019. 1 fund tracked by Wall St. Rank holds AXLA as of Q4 2023.

  • UBS Group reported no remaining Axcella Health Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • UBS Group sold 106 Axcella Health Inc. Common Stock shares in Q4 2023, an estimated $1.11K.
  • UBS Group first reported a position in Axcella Health Inc. Common Stock in Q2 2019 and held it in 17 quarters.
  • UBS Group's Axcella Health Inc. Common Stock position peaked at $76K in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Axcella Health Inc. Common Stock as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.